Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Capital Expenditures (2016 - 2025)

Iradimed (IRMD) has disclosed Capital Expenditures for 13 consecutive years, with -$5.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 219.06% to -$5.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.9 million, a 243.3% decrease, with the full-year FY2024 number at $811753.0, up 43.25% from a year prior.
  • Capital Expenditures was -$5.8 million for Q3 2025 at Iradimed, down from $2.6 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.4 million in Q2 2023 to a low of -$6.3 million in Q4 2023.
  • A 5-year average of $169343.2 and a median of $208237.0 in 2024 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 2653.59% in 2023; the steepest drop was 41030.75% in 2023.
  • Iradimed's Capital Expenditures stood at $312091.0 in 2021, then plummeted by 104.94% to -$15419.0 in 2022, then crashed by 41030.75% to -$6.3 million in 2023, then skyrocketed by 30.57% to -$4.4 million in 2024, then plummeted by 31.71% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Capital Expenditures are -$5.8 million (Q3 2025), $2.6 million (Q2 2025), and $3.7 million (Q1 2025).